Logo image of ETNB

89BIO INC (ETNB) Stock Fundamental Analysis

NASDAQ:ETNB - Nasdaq - US2825591033 - Common Stock - Currency: USD

9.65  +0.04 (+0.42%)

After market: 9.65 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ETNB. ETNB was compared to 561 industry peers in the Biotechnology industry. ETNB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ETNB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ETNB has reported negative net income.
ETNB had a negative operating cash flow in the past year.
In the past 5 years ETNB always reported negative net income.
In the past 5 years ETNB always reported negative operating cash flow.
ETNB Yearly Net Income VS EBIT VS OCF VS FCFETNB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

ETNB has a Return On Assets of -56.45%. This is comparable to the rest of the industry: ETNB outperforms 41.71% of its industry peers.
ETNB has a Return On Equity (-63.86%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -56.45%
ROE -63.86%
ROIC N/A
ROA(3y)-50.79%
ROA(5y)-46.26%
ROE(3y)-61.77%
ROE(5y)-56.24%
ROIC(3y)N/A
ROIC(5y)N/A
ETNB Yearly ROA, ROE, ROICETNB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ETNB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ETNB Yearly Profit, Operating, Gross MarginsETNB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ETNB has been increased compared to 1 year ago.
The number of shares outstanding for ETNB has been increased compared to 5 years ago.
ETNB has a worse debt/assets ratio than last year.
ETNB Yearly Shares OutstandingETNB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ETNB Yearly Total Debt VS Total AssetsETNB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 7.93 indicates that ETNB is not in any danger for bankruptcy at the moment.
ETNB's Altman-Z score of 7.93 is amongst the best of the industry. ETNB outperforms 84.31% of its industry peers.
ETNB has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
ETNB has a worse Debt to Equity ratio (0.06) than 63.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 7.93
ROIC/WACCN/A
WACCN/A
ETNB Yearly LT Debt VS Equity VS FCFETNB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

ETNB has a Current Ratio of 18.03. This indicates that ETNB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 18.03, ETNB belongs to the best of the industry, outperforming 92.34% of the companies in the same industry.
ETNB has a Quick Ratio of 18.03. This indicates that ETNB is financially healthy and has no problem in meeting its short term obligations.
ETNB has a Quick ratio of 18.03. This is amongst the best in the industry. ETNB outperforms 92.51% of its industry peers.
Industry RankSector Rank
Current Ratio 18.03
Quick Ratio 18.03
ETNB Yearly Current Assets VS Current LiabilitesETNB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ETNB have decreased strongly by -68.16% in the last year.
EPS 1Y (TTM)-68.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.91% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.99%
EPS Next 2Y15.6%
EPS Next 3Y10.67%
EPS Next 5Y13.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ETNB Yearly Revenue VS EstimatesETNB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
ETNB Yearly EPS VS EstimatesETNB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ETNB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ETNB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ETNB Price Earnings VS Forward Price EarningsETNB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ETNB Per share dataETNB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.6%
EPS Next 3Y10.67%

More info and screens

0

5. Dividend

5.1 Amount

ETNB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

89BIO INC

NASDAQ:ETNB (5/22/2025, 4:30:02 PM)

After market: 9.65 0 (0%)

9.65

+0.04 (+0.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners100.95%
Inst Owner Change29.11%
Ins Owners1.33%
Ins Owner Change19.69%
Market Cap1.41B
Analysts84.71
Price Target30.6 (217.1%)
Short Float %12.02%
Short Ratio8.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.1%
Min EPS beat(2)-29.63%
Max EPS beat(2)3.43%
EPS beat(4)2
Avg EPS beat(4)-30.31%
Min EPS beat(4)-112.45%
Max EPS beat(4)17.4%
EPS beat(8)4
Avg EPS beat(8)-17.78%
EPS beat(12)6
Avg EPS beat(12)-8.07%
EPS beat(16)8
Avg EPS beat(16)-8.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.91%
PT rev (3m)-0.41%
EPS NQ rev (1m)-10.3%
EPS NQ rev (3m)20.43%
EPS NY rev (1m)-2.45%
EPS NY rev (3m)19.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.33
P/tB 2.33
EV/EBITDA N/A
EPS(TTM)-3.38
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-2.74
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS0
BVpS4.15
TBVpS4.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.45%
ROE -63.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.79%
ROA(5y)-46.26%
ROE(3y)-61.77%
ROE(5y)-56.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.03
Quick Ratio 18.03
Altman-Z 7.93
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)20.59%
Cap/Depr(5y)70.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-68.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.26%
EPS Next Y37.99%
EPS Next 2Y15.6%
EPS Next 3Y10.67%
EPS Next 5Y13.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-124.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.71%
EBIT Next 3Y-4.05%
EBIT Next 5YN/A
FCF growth 1Y-360.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-360.43%
OCF growth 3YN/A
OCF growth 5YN/A